Health Care › BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

KYMR Price Correlated With Financials For Kymera Therapeutics

Free historical financial statements for Kymera Therapeutics Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 9 quarters since 2020. Compare with KYMR stock chart to see long term trends.

KYMR Stock Compared to Quarterly

log linear

KYMR Income Statement

Revenue, Net:

Revenue Per Share:

Selling, General & Admin Expense:

Research & Development Expense:

Total Operating Expenses:

Operating Income:

Income Taxes:

Net Income:

Earnings Per Share, Basic:

Shares Outstanding, Basic Avg:

KYMR Cash Flow

Operating Activities Net Income:

Depreciation, Depletion & Amortization:

Net Cash from Operations:

Net Cash from Operations Per Share:

Net Cash from Financing Activities:

Property, Plant & Equipment Purchases:

Net Cash from Investing Activities:

Net Change in Cash & Equivalents:

KYMR Balance Sheet

Cash and Cash Equivalents:

Total Current Assets:

Property, Plant & Equipment, Net:

Total Assets:

Accounts Payable:

Total Short-Term Liabilities:

Total Liabilities:

Insider Trading

Change

Value

Transaction

SEC Form 4

BVF PARTNERS L P/IL Director

41,007 sh at $31

$1,251,191

Buy

2023-01-13

Major Holders (from 13F filings)

Investment Type

Change

Value (x$1000)

increase or decrease

Atlas Venture Life Science Advisors, LLC

6,875,698 sh

$149,684

BVF Inc Il

4,692,604 sh

553,846 sh
13%

$102,158

$20,666

Price T Rowe Associates Inc /Md/

4,097,712 sh

-1,126,974 sh
-22%

$89,208

-$13,666

Wellington Management Group Llp

3,410,386 sh

-1,624,554 sh
-32%

$74,245

-$24,892

Blackrock Inc.

3,204,682 sh

376,248 sh
13%

$69,767

$14,076

Baker Bros. Advisors Lp

2,879,825 sh

$62,694

Redmile Group, LLC

2,876,637 sh

269,507 sh
10%

$62,624

$11,290

Vanguard Group Inc

2,863,177 sh

-11,547 sh
0%

$62,332

$5,728

State Street Corp

2,685,404 sh

-829,034 sh
-24%

$58,461

-$10,738

Avoro Capital Advisors LLC

2,169,230 sh

909,230 sh
72%

$47,224

$22,415

Artal Group S.A.

1,500,000 sh

500,000 sh
50%

$32,655

$12,965

Wasatch Advisors Inc

1,060,561 sh

489,917 sh
86%

$23,088

$11,852

Rock Springs Capital Management Lp

1,046,743 sh

270,864 sh
35%

$22,788

$7,511

Bank Of New York Mellon Corp

1,025,244 sh

582 sh
0%

$22,318

$2,143

Ecor1 Capital, LLC

796,093 sh

796,093 sh
NEW

$17,331

Geode Capital Management, LLC

701,222 sh

25,375 sh
4%

$15,265

$1,958

Deer Management Co. LLC

615,895 sh

$13,408

JPMorgan Chase & Co

561,872 sh

-41,506 sh
-7%

$12,232

$352

Candriam Luxembourg S.C.A.

549,618 sh

79,758 sh
17%

$11,966

$2,715

Pictet Asset Management SA

482,001 sh

-164,074 sh
-25%

$10,494

-$2,227

Data imported from Kymera Therapeutics Inc. SEC filings. Check original filings before making any investment decision.